SpringWorks Therapeutics (SWTX)
(Delayed Data from NSDQ)
$38.04 USD
+1.17 (3.17%)
Updated Jul 26, 2024 04:00 PM ET
After-Market: $38.00 -0.04 (-0.11%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
Brokerage Reports
0 items in cart
SpringWorks Therapeutics [SWTX]
Reports for Purchase
Showing records 181 - 195 ( 195 total )
Company: SpringWorks Therapeutics
Industry: Medical - Biomedical and Genetics
Belantamab Mafodotin European Regulatory Application Accepted; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: SpringWorks Therapeutics
Industry: Medical - Biomedical and Genetics
Company: SpringWorks Therapeutics
Industry: Medical - Biomedical and Genetics
GSK''s Belantamab Snags Priority Review; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: SpringWorks Therapeutics
Industry: Medical - Biomedical and Genetics
Allogene Collaboration an Incremental Positive; Reiterate Buy; Raising PT to $40
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: SpringWorks Therapeutics
Industry: Medical - Biomedical and Genetics
Multiple Matches for Niro in Multiple Myeloma
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: SpringWorks Therapeutics
Industry: Medical - Biomedical and Genetics
We Still See Solid Potential for Nirogacestat in Multiple Myeloma Despite Lower DREAMM-2 Efficacy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: SpringWorks Therapeutics
Industry: Medical - Biomedical and Genetics
Keytruda Shows Promising, But Not Unbeatable, Efficacy in 1L KRAS+ NSCLC; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: SpringWorks Therapeutics
Industry: Medical - Biomedical and Genetics
Company: SpringWorks Therapeutics
Industry: Medical - Biomedical and Genetics
Competitive Landscape and Belantamab + Nirogacestat Update From ASH; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: SpringWorks Therapeutics
Industry: Medical - Biomedical and Genetics
Nirogacestat Multiple Myeloma Rationale Strengthened at ASH 2019; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: SpringWorks Therapeutics
Industry: Medical - Biomedical and Genetics
Company: SpringWorks Therapeutics
Industry: Medical - Biomedical and Genetics
Company: SpringWorks Therapeutics
Industry: Medical - Biomedical and Genetics
Company: SpringWorks Therapeutics
Industry: Medical - Biomedical and Genetics
Initiating at OUTPERFORM; Drink Deep or Taste not this Pierian Spring... Works
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D